Janku, Filip
Huang, Helen J.
Pereira, David Y.
Kobayashi, Masae
Chiu, Chung Hei
Call, S. Greg
Woodbury, Kristen T.
Chao, Felix
Marshak, Daniel R.
Chiu, Ricky Y. T.
Funding for this research was provided by:
Rising Tide Foundation
Andrew Sabin Family Foundation
Phase Scientific International Ltd
Article History
Received: 23 March 2021
Accepted: 13 September 2021
First Online: 4 October 2021
Competing interests
: Filip Janku has research support from Novartis, Genentech, BioMed Valley Discoveries, Astellas, Agios, Plexxikon, Deciphera, Piqur, Symphogen, Bristol-Myers Squibb, Asana, Ideaya Biosciences, Synthorx, FujiFilm Pharmaceuticals, Sotio and Proximagen; is or has been on the Scientific Advisory Boards of Guardant Health, Illumina, Ideaya Biosciences, IFM Therapeutics, Synlogic, Sotio, Puretech Health and Deciphera; is a paid consultant for Cardiff Oncology and Immunomet; and has ownership interests in Cardiff Oncology. Daniel Marshak is a member of the Board of Directors for: Tecan (SIX:TECN) , InVivo Therapeutics (NASDAQ:NVIV), LifeVault Bio Inc., and Elevian Inc., he serves on an Advisory Board for Catalent, Inc. (NYSE:CTLT), and he maintains an equity position in PerkinElmer (NYSE:PKI). Ricky Chiu, Felix Chao, Daniel Marshak, David Pereira, and Masae Kobayashi all have an equity interest and employment with Phase Scientific International Ltd. Helen Huang, Chung Hei Chiu, S. Greg Call, and Kristen Woodbury declare no competing interests.